Almirall

FDA Clears Sun Pharma's ILUMYA for Psoriatic Arthritis in Adults

Image
FDA Clears Sun Pharma's ILUMYA for Psoriatic Arthritis in Adults

Mumbai – October 30, 2026 -- The U.S. Food and Drug Administration has approved Sun Pharma's supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) in adults with active psoriatic arthritis (PsA), the first expansion of the IL-23 inhibitor beyond plaque psoriasis since its 2018 U.S. approval.

Approval addresses a U.S. patient pool of about 2.4 million

Approximately 2.4 million Americans live with PsA, according to Sun Pharma. The company states that roughly 1 in 3 people with psoriasis also have PsA, and that more than 15% of psoriasis patients may have undiagnosed PsA.

ILUMYA was previously cleared only for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Lilly's EBGLYSS Hits Primary Endpoint in Phase 3b Hand-Foot Eczema Trial

Image
Lilly's EBGLYSS Hits Primary Endpoint in Phase 3b Hand-Foot Eczema Trial

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) said its EBGLYSS (lebrikizumab-lbkz) monotherapy met the primary and secondary endpoints of the Phase 3b ADtouch study at Week 16, with more than half of treated patients achieving clear or almost clear skin on hands and feet (HF-IGA 0/1), the company disclosed ahead of the European Academy of Dermatology and Venereology Congress in Vienna, running Sept. 30-Oct. 3.

Trial enrolled 221 patients with moderate-to-severe hand and foot atopic dermatitis

The randomized, double-blind, placebo-controlled ADtouch trial (NCT06921759) assigned 221 adults and adolescents 1:1 to EBGLYSS 250 mg or placebo every two weeks over 16 weeks, following an initial loading dose. Participants had an inadequate response to topical therapies and applied moisturizer throughout the study.